COLUMBIA, S.C. (May 9, 2023) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose vial product, Albuterol Sulfate Inhalation Solution 0.5% (5 mg/mL). It is a ready-to-use drug shortage solution for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 27-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.
Joining a growing portfolio of 503B single-dose products, Albuterol Sulfate comes in a vial with a beyond-use-date of 60 days and is preservative free, is labeled to meet medication safety standards, and can be stored at room temperature. This product hits the market as the U.S. Food & Drug Administration (FDA) recently reported a national shortage for Albuterol Sulfate, an FDA deemed “essential medication.”
“Major shifts in the market’s ability to meet demand has driven our rapid response,” said Jody Chastain, President and CEO of The Ritedose Corporation. “Our manufacturing flexibility is ideally suited to step into this role. Our now available supply of Albuterol Sulfate will return stability to the market and ease concerns for healthcare providers and Albuterol patients across the country.”
Founded in 1995 in Columbia, South Carolina, The Ritedose Corporation is an industry leader in the aseptic manufacturing and liquid packaging of drug products and utilizes proven Blow-Fill-Seal (BFS) equipment and processes to ensure efficient, consistent and safe dosage delivery. The company’s 27-year track record includes delivery of more than 10 billion doses since 2012 without interruption, and its current capacity is 2 billion units annually.